Amyloid-Beta MAbs Offer Little Benefit in Alzheimer’s, but ALZ-801 Shows MCI Efficacy
Jul 31, 2026
A Cochrane review of 17 trials finds amyloid-beta-targeted monoclonal antibodies offer negligible benefit in MCI or mild Alzheimer’s. In a phase 3 trial, the oral agent valiltramiprosate (ALZ-801) showed significant cognitive and functional improvements in the MCI subgroup, with no brain swelling risk. The company plans another phase 3 study in 2026.